ReviewCurrent drug targets2026
Mechanistic Approach to Ferroptosis in Cancer and Neurological Diseases.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is a form of oxidative, iron-dependent, non-apoptotic cell death characterized by the accumulation of lipid peroxides and the depletion of glutathione. Ferroptosis plays a significant role in human cancer and is essential in neurological disorders, including neurodegeneration, stroke, and neurotrauma. One of the key challenges in cancer research is how to effectively kill cancer cells while leaving healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the main reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. It is a newly identified regulated form of cell death, which is thought to play a major role in neurodegenerative diseases. The mechanisms of ferroptosis in several neurological disorders are discussed in detail in this article. It also provides an overview of emerging medications that target ferroptosis in the treatment of neurological disorders. It also highlights the variations and connections between the different cell death pathways implicated in neurological disorders. Clarifying the function of ferroptosis in the brain will help us better understand the mechanisms behind neurological disorders and offer possible strategies for both acute and long-term neurological illness prevention and therapy. Consequently, we provide an overview and brief description of the main pathways involved in ferroptosis in this review, focusing on its regulation and its dual roles as a tumor suppressor and an oncogenic process in various human malignancies. The identification of FDA-approved drugs as ferroptosis inducers has raised high expectations for ferroptosis as a promising new approach to killing therapy-resistant cancers.
Indexed as
Identifiers
41603173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.